Clinical Research Directory
Browse clinical research sites, groups, and studies.
Daily Tadalafil as Adjunctive Therapy Versus Monotherapy for PDE5 Inhibitor-Resistant Erectile Dysfunction
Sponsor: Al-Azhar University
Summary
This randomized trial will compare daily tadalafil 5 mg as adjunct therapy versus monotherapy in men with on-demand PDE5 inhibitor-resistant erectile dysfunction. The study will evaluate changes in erectile function, treatment satisfaction, partner satisfaction, and safety over 12 weeks.
Official title: Efficacy of Daily 5-mg Tadalafil as Adjunctive Therapy Versus Monotherapy in Men With On-Demand PDE5 Inhibitor-Resistant Erectile Dysfunction: A Prospective Randomized Trial
Key Details
Gender
MALE
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
260
Start Date
2026-07-30
Completion Date
2027-06-30
Last Updated
2026-08-10
Healthy Volunteers
No
Conditions
Interventions
Tadalafil; Current on-demand PDE5 inhibitor
Tadalafil 5 mg orally once daily for 12 weeks plus the participant's current effective on-demand PDE5 inhibitor, taken 1-2 hours before sexual activity, with a maximum of once daily.
Tadalafil 5 mg
Tadalafil 5 mg orally once daily for 12 weeks.